Stay updated on First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.

Latest updates to the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page
- Check5 days agoChange DetectedVersion tag updated from v3.0.1 to v3.0.2; the old tag was removed and the 'Back to Top' link was deleted.SummaryDifference0.2%
- Check12 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check19 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations, as well as updated drug information for Tarlatamab, Durvalumab, and Atezolizumab. Notably, several previous entries related to lung cancer and specific locations have been removed.SummaryDifference8%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check48 days agoChange DetectedThe web page has been updated to version 2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
Stay in the know with updates to First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.